Q&A: Poolbeg Pharma CEO Jeremy Skillington on its groundbreaking AI collaboration
Jeremy Skillington, CEO of (POLB ), talks us through the results of its successful collaboration with leading AI specialist CytoReason, making at a pioneer in AI-enabled drug discovery.
0:28 Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment.
2:07 How the approach to analyse human challenge data for influenza with AI is the first of its kind.
3:28 Next steps after the successful conclusion of the collaboration, moving towards partnership.
4:54 Why Poolbeg is at the forefront of AI-enabled drug discovery
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.